 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | QL-007 / Qilu Pharma
Journal: A novel hepatitis B virus capsid assembly modulator QL-007 inhibits HBV replication and infection through altering capsid assembly. (Pubmed Central) - Sep 9, 2023
Mechanistically, QL-007 blocked the encapsidation of pgRNA and induced aberrant polymers assembly at concentrations ?100?nM, while having no impact on the stability of core proteins. In conclusion, our findings underscore the potential of QL-007 as an effective agent against HBV replication and introduce it as a novel CpAM for the antiviral treatment of chronic hepatitis B.
- |||| QL-007 / Qilu Pharma
New P2 trial, Combination therapy: An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b (clinicaltrials.gov) - Nov 14, 2019
P2, N=100, Recruiting, Sponsor: Qilu Pharmaceutical Co., Ltd.
- |||| QL-007 / Qilu Pharma
New P2 trial, Combination therapy: An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy (clinicaltrials.gov) - Nov 8, 2019
P2, N=60, Recruiting, Sponsor: Qilu Pharmaceutical Co., Ltd.
- ||| QL-007 / Qilu Pharma
New P1 trial: A Study to Investigate the Safety, Efficacy and PK of Multiple Doses of QL-007 in Chronic Hepatitis B Patients in CHINA (clinicaltrials.gov) - Dec 10, 2018
P1b, N=60, Recruiting, Sponsor: Qilu Pharmaceutical Co., Ltd.
- | QL-007 / Qilu Pharma
Enrollment open, Trial completion date, Trial primary completion date: A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients (clinicaltrials.gov) - Jul 16, 2018
P1b, N=18, Recruiting, Sponsor: Qilu Pharmaceutical Co., Ltd.
In conclusion, our findings underscore the potential of QL-007 as an effective agent against HBV replication and introduce it as a novel CpAM for the antiviral treatment of chronic hepatitis B. Not yet recruiting --> Recruiting | Trial completion date: Aug 2018 --> Dec 2018 | Trial primary completion date: Mar 2018 --> Oct 2018
- | QL-007 / Qilu Pharma
New P1 trial: A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients (clinicaltrials.gov) - Aug 8, 2017
P1b, N=18, Not yet recruiting, Sponsor: Qilu Pharmaceutical Co., Ltd.